Management of immune suppression in systemic diseases affecting the kidney;Manejo de la inmunosupresión en enfermedades sistémicas que afectan al riñón

Nefrologia

Volumn 28, Issue SUPPL. 5, 2008, Pages 91-96

  Ballarin J ^a   Diaz M ^a  

^a FUNDACIÓ PUIGVERT   (Spain)

Author keywords

AA amyloidosis; AL amyloidosis; Lupic nephropathy; Small vessel vasculitis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; RITUXIMAB;

AMYLOIDOSIS; CHRONIC KIDNEY FAILURE; DRUG COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; VASCULITIS;

ADRENAL CORTEX HORMONES; AMYLOIDOSIS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MELPHALAN; MYCOPHENOLIC ACID; PLASMA EXCHANGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; VASCULITIS;

EID: 55949109131     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Quereda C, García-López F, Álvarez-Rangel LE, Galeano G, Pascual J, Praga M. Alternativas al tratamiento con ciclofosfamida en la nefritis lúpica. Nefrología 2006; Supl. 5: 38-47.
2. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2007; 2: 968-75.
3. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT y cols. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28.
4. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R y cols. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005; 10: 504-10.
5. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-84.
6. Flores-Suárez LF, Villa AR. Open randomized trial comparing mycophenolate mofetil versus intravenous cyclophosphamide as induction therapy for severe lupus nephritis. J Am Soc Nephrol 2004; 15: PO257.
7. Pepper RJ, Pusey C. Treament of Lupus nephritis without maintenance steroids. ASN 2007.
8. Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW, Van Vollenhoven RF. Histopathologic and clinical outcome of Rituximab treatment in patients with Cyclophosphamide resistant Lupus Nephritis. Arthritis Rheum 2007; 56: 1263-1272 [SUPO1055].
9. . Flossmann O, Harper L, Heij C, Hoglund P, Jayne DRW, Luqmani RA, Westman K, The European Vasculitis Study Group Vasculitis. Outcome of ANCA Associated Vasculitis - Long-Term Follow up of Four Randomised Controlled Trials. ASN 2007 [SU-PO1055].
10. Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, Mirapeix E, Savage CO, Sinico RA, Stegeman CA, Westman KW, Van der Woude FJ, De Lind van Wijngaarden RA, Pusey CD; European Vasculitis Study Group. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-8.
11. Matthew D. Morgan MD, Harper L. Infliximab as Additional Therapy in Anti-Neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis. ASN 2007 [SU-PO922].
12. Walsh M, Merkel P, Mahr A, Jayne DRW. A Systematic Review and Meta-Analysis of Relapses in ANCA-Associated Vasculitis (AAV): What Is the Effect of Low-Dose Corticosteroids? ASN 2007 [SU-PO919].
13. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66: 798-802.
14. Jones R, Ferraro A, Brogan P, Salama, Savage C, Short A, Jayne D. A Multi-Centre Survey of Rituximab for Refractory ANCA Associated Vasculitis [SA-FC061] ASN 2007.
15. Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP; Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 13 (357): 1083-93.
16. Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puéchal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 7 (356): 2349-60.